Raymond James Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $140

Benzinga Newsdesk www.benzinga.com Positive 50.6%

Neg 0% Neu 0% Pos 50.6%

Raymond James analyst Thomas Deal initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announces Price Target of $140.